a statistical trendp = 0.052
Post-hoc testing revealed a statistical trend for a greater response to infliximab versus placebo in patients with CRP >3 mg/L (p = 0.052).
Post-hoc testing revealed a statistical trend for a greater response to infliximab versus placebo in patients with CRP >3 mg/L (p = 0.052).